NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation

Steven Z. Pavletic, Shaji K Kumar, Mohamad Mohty, Marcos de Lima, James M Foran, Marcelo Pasquini, Mei Jie Zhang, Sergio Giralt, Michael R. Bishop, Daniel Weisdorf

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly being used for treatment of hematologic malignancies, and the immunologic graft-versus-tumor effect (GVT) provides its therapeutic effectiveness. Disease relapse remains a cause of treatment failure in a significant proportion of patients undergoing alloHSCT without improvements over the last 2-3 decades. We summarize here current data and outline future research regarding the epidemiology, risk factors, and outcomes of relapse after alloHSCT. Although some factors (eg, disease status at alloHSCT or graft-versus-host disease [GVHD] effects) are common, other disease-specific factors may be unique. The impact of reduced-intensity regimens on relapse and survival still need to be assessed using contemporary supportive care and comparable patient populations. The outcome of patients relapsing after an alloHSCT generally remains poor even though interventions including donor leukocyte infusions can benefit some patients. Trials examining targeted therapies along with improved safety of alloHSCT may result in improved outcomes, yet selection bias necessitates prospective assessment to gauge the real contribution of any new therapies. Ongoing chronic GVHD (cGVHD) or other residual post-alloHSCT morbidities may limit the applicability of new therapies. Developing strategies to promptly identify patients as alloHSCT candidates, while malignancy is in a more treatable stage, could decrease relapses rates after alloHSCT. Better understanding and monitoring of minimal residual disease posttransplant could lead to novel preemptive treatments of relapse. Analyses of larger cohorts through multicenter collaborations or registries remain essential to probe questions not amenable to single center or prospective studies. Studies need to provide data with detail on disease status, prior treatments, biologic markers, and posttransplant events. Stringent statistical methods to study relapse remain an important area of research. The opportunities for improvement in prevention and management of post-alloHSCT relapse are apparent, but clinical discipline in their careful study remains important.

Original languageEnglish (US)
Pages (from-to)871-890
Number of pages20
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number7
DOIs
StatePublished - Jul 2010

Fingerprint

Hematopoietic Stem Cell Transplantation
Cell Transplantation
Homologous Transplantation
Secondary Prevention
Epidemiology
Education
Recurrence
Therapeutics
Graft vs Host Disease
Selection Bias
Residual Neoplasm
Hematologic Neoplasms
Treatment Failure
Registries
Neoplasms
Patient Care
Leukocytes
Cohort Studies
Biomarkers
Tissue Donors

Keywords

  • Allogeneic hematorpoietic stem cell transplantation
  • Relapse

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation : Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. / Pavletic, Steven Z.; Kumar, Shaji K; Mohty, Mohamad; de Lima, Marcos; Foran, James M; Pasquini, Marcelo; Zhang, Mei Jie; Giralt, Sergio; Bishop, Michael R.; Weisdorf, Daniel.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 7, 07.2010, p. 871-890.

Research output: Contribution to journalArticle

@article{4d7ecbc908bf49b489b19b8f07505e4b,
title = "NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation",
abstract = "Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly being used for treatment of hematologic malignancies, and the immunologic graft-versus-tumor effect (GVT) provides its therapeutic effectiveness. Disease relapse remains a cause of treatment failure in a significant proportion of patients undergoing alloHSCT without improvements over the last 2-3 decades. We summarize here current data and outline future research regarding the epidemiology, risk factors, and outcomes of relapse after alloHSCT. Although some factors (eg, disease status at alloHSCT or graft-versus-host disease [GVHD] effects) are common, other disease-specific factors may be unique. The impact of reduced-intensity regimens on relapse and survival still need to be assessed using contemporary supportive care and comparable patient populations. The outcome of patients relapsing after an alloHSCT generally remains poor even though interventions including donor leukocyte infusions can benefit some patients. Trials examining targeted therapies along with improved safety of alloHSCT may result in improved outcomes, yet selection bias necessitates prospective assessment to gauge the real contribution of any new therapies. Ongoing chronic GVHD (cGVHD) or other residual post-alloHSCT morbidities may limit the applicability of new therapies. Developing strategies to promptly identify patients as alloHSCT candidates, while malignancy is in a more treatable stage, could decrease relapses rates after alloHSCT. Better understanding and monitoring of minimal residual disease posttransplant could lead to novel preemptive treatments of relapse. Analyses of larger cohorts through multicenter collaborations or registries remain essential to probe questions not amenable to single center or prospective studies. Studies need to provide data with detail on disease status, prior treatments, biologic markers, and posttransplant events. Stringent statistical methods to study relapse remain an important area of research. The opportunities for improvement in prevention and management of post-alloHSCT relapse are apparent, but clinical discipline in their careful study remains important.",
keywords = "Allogeneic hematorpoietic stem cell transplantation, Relapse",
author = "Pavletic, {Steven Z.} and Kumar, {Shaji K} and Mohamad Mohty and {de Lima}, Marcos and Foran, {James M} and Marcelo Pasquini and Zhang, {Mei Jie} and Sergio Giralt and Bishop, {Michael R.} and Daniel Weisdorf",
year = "2010",
month = "7",
doi = "10.1016/j.bbmt.2010.04.004",
language = "English (US)",
volume = "16",
pages = "871--890",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

T2 - Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation

AU - Pavletic, Steven Z.

AU - Kumar, Shaji K

AU - Mohty, Mohamad

AU - de Lima, Marcos

AU - Foran, James M

AU - Pasquini, Marcelo

AU - Zhang, Mei Jie

AU - Giralt, Sergio

AU - Bishop, Michael R.

AU - Weisdorf, Daniel

PY - 2010/7

Y1 - 2010/7

N2 - Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly being used for treatment of hematologic malignancies, and the immunologic graft-versus-tumor effect (GVT) provides its therapeutic effectiveness. Disease relapse remains a cause of treatment failure in a significant proportion of patients undergoing alloHSCT without improvements over the last 2-3 decades. We summarize here current data and outline future research regarding the epidemiology, risk factors, and outcomes of relapse after alloHSCT. Although some factors (eg, disease status at alloHSCT or graft-versus-host disease [GVHD] effects) are common, other disease-specific factors may be unique. The impact of reduced-intensity regimens on relapse and survival still need to be assessed using contemporary supportive care and comparable patient populations. The outcome of patients relapsing after an alloHSCT generally remains poor even though interventions including donor leukocyte infusions can benefit some patients. Trials examining targeted therapies along with improved safety of alloHSCT may result in improved outcomes, yet selection bias necessitates prospective assessment to gauge the real contribution of any new therapies. Ongoing chronic GVHD (cGVHD) or other residual post-alloHSCT morbidities may limit the applicability of new therapies. Developing strategies to promptly identify patients as alloHSCT candidates, while malignancy is in a more treatable stage, could decrease relapses rates after alloHSCT. Better understanding and monitoring of minimal residual disease posttransplant could lead to novel preemptive treatments of relapse. Analyses of larger cohorts through multicenter collaborations or registries remain essential to probe questions not amenable to single center or prospective studies. Studies need to provide data with detail on disease status, prior treatments, biologic markers, and posttransplant events. Stringent statistical methods to study relapse remain an important area of research. The opportunities for improvement in prevention and management of post-alloHSCT relapse are apparent, but clinical discipline in their careful study remains important.

AB - Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly being used for treatment of hematologic malignancies, and the immunologic graft-versus-tumor effect (GVT) provides its therapeutic effectiveness. Disease relapse remains a cause of treatment failure in a significant proportion of patients undergoing alloHSCT without improvements over the last 2-3 decades. We summarize here current data and outline future research regarding the epidemiology, risk factors, and outcomes of relapse after alloHSCT. Although some factors (eg, disease status at alloHSCT or graft-versus-host disease [GVHD] effects) are common, other disease-specific factors may be unique. The impact of reduced-intensity regimens on relapse and survival still need to be assessed using contemporary supportive care and comparable patient populations. The outcome of patients relapsing after an alloHSCT generally remains poor even though interventions including donor leukocyte infusions can benefit some patients. Trials examining targeted therapies along with improved safety of alloHSCT may result in improved outcomes, yet selection bias necessitates prospective assessment to gauge the real contribution of any new therapies. Ongoing chronic GVHD (cGVHD) or other residual post-alloHSCT morbidities may limit the applicability of new therapies. Developing strategies to promptly identify patients as alloHSCT candidates, while malignancy is in a more treatable stage, could decrease relapses rates after alloHSCT. Better understanding and monitoring of minimal residual disease posttransplant could lead to novel preemptive treatments of relapse. Analyses of larger cohorts through multicenter collaborations or registries remain essential to probe questions not amenable to single center or prospective studies. Studies need to provide data with detail on disease status, prior treatments, biologic markers, and posttransplant events. Stringent statistical methods to study relapse remain an important area of research. The opportunities for improvement in prevention and management of post-alloHSCT relapse are apparent, but clinical discipline in their careful study remains important.

KW - Allogeneic hematorpoietic stem cell transplantation

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=77953587073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953587073&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.04.004

DO - 10.1016/j.bbmt.2010.04.004

M3 - Article

VL - 16

SP - 871

EP - 890

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -